Dendreon is a company headquartered in the United States.
Dendreon develops and manufactures cellular immunotherapies, including Provenge, the first FDA-approved cellular immunotherapy for prostate cancer.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.